rethinkTHC Search
Menu
Study breakdown

Blocking endocannabinoid breakdown reduced opioid withdrawal symptoms in mice

Animal StudyPreliminary evidence
The takeaway

Mice given drugs that boosted their natural endocannabinoids showed fewer opioid withdrawal symptoms, with the 2-AG pathway showing broader effects than anandamide.

Read this if you want to understand how the endocannabinoid system connects to opioid withdrawal.

MAGL inhibitor reduced most withdrawal symptoms; FAAH inhibitor helped only some

What the researchers found

Morphine-dependent mice challenged with naloxone displayed jumping, paw tremors, diarrhea, and weight loss. The researchers tested two strategies to boost endocannabinoids: blocking MAGL (which breaks down 2-AG) and blocking FAAH (which breaks down anandamide).

The MAGL inhibitor JZL184 reduced most withdrawal symptoms in a dose-dependent manner through CB1 receptors. It also reduced spontaneous withdrawal signs, not just those triggered by naloxone.

The FAAH inhibitor PF-3845 reduced jumping and paw tremors through CB1 receptors but did not help with diarrhea or weight loss. This suggested 2-AG and anandamide play different roles in opioid withdrawal.

Why it matters

Opioid withdrawal is a major barrier to quitting. These findings suggested that boosting the body's own cannabinoids, rather than using external cannabis, could reduce withdrawal severity while potentially avoiding the side effects of direct cannabinoid agonists.

The numbers in context

JZL184 dose-dependently reduced most withdrawal symptoms. PF-3845 reduced jumping and paw tremors but not diarrhea or weight loss. Both effects were blocked by CB1 antagonist rimonabant, confirming the mechanism.

How the study worked

Morphine-dependent mice received naloxone to precipitate withdrawal. Researchers tested MAGL inhibitor JZL184 and FAAH inhibitor PF-3845 at multiple doses, using CB1 and CB2 antagonists to confirm receptor mechanisms. An isolated ileum preparation tested gut-level effects.

What this study cannot tell us

Mouse study only. The doses and routes of administration may not translate to humans. Naloxone-precipitated withdrawal is more abrupt than natural withdrawal. Long-term effects of endocannabinoid enzyme inhibition were not assessed.

How to read the evidence

Animal study with clear mechanistic findings. Strong internal design with receptor antagonist controls, but no human data.

When this study was published

Published in 2011. Research on endocannabinoid enzyme inhibitors for addiction has continued to develop.

The bigger picture

This study contributed to a growing body of evidence connecting the endocannabinoid and opioid systems. The approach of boosting natural endocannabinoids rather than administering external cannabinoids represents a more targeted therapeutic strategy.

Questions still open

  • Would MAGL inhibitors work in human opioid withdrawal? Could combining FAAH and MAGL inhibitors produce broader symptom relief? What are the long-term safety implications of sustained endocannabinoid elevation?

Common questions

Is this the same as using cannabis for opioid withdrawal?
No. Instead of introducing external cannabinoids, this approach boosts the body's own endocannabinoids by blocking the enzymes that break them down. This is a more targeted strategy that may avoid some side effects of cannabis use.
Why did the two approaches work differently?
Anandamide (boosted by FAAH inhibition) and 2-AG (boosted by MAGL inhibition) act on overlapping but different pathways. 2-AG is present at higher concentrations and may have broader effects on withdrawal symptoms.

Read the original research

Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.

The Journal of pharmacology and experimental therapeutics, 339(1), 173-85

Citation

Ramesh, Divya; Ross, Gracious R; Schlosburg, Joel E; Owens, Robert A; Abdullah, Rehab A; Kinsey, Steven G; Long, Jonathan Z; Nomura, Daniel K; Sim-Selley, Laura J; Cravatt, Benjamin F; Akbarali, Hamid I; Lichtman, Aron H. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.. The Journal of pharmacology and experimental therapeutics, 339(1), 173-85. https://doi.org/10.1124/jpet.111.181370

Explore the wider topic